Arcutis Biotherapeutics, Inc. (ARQT)

Market Cap	3.61B
Revenue (ttm)	317.93M
Net Income (ttm)	-44.32M
Shares Out	122.49M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	78.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,594,315
Open	27.15
Previous Close	27.33
Day's Range	27.08 - 30.01
52-Week Range	10.03 - 30.01
Beta	1.72
Analysts	Strong Buy
Price Target	22.17 (-24.82%)
Earnings Date	Oct 28, 2025

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2020
• Employees: 342
• Stock Exchange: NASDAQ
• Ticker Symbol: ARQT
• Website: https://www.arcutis.com

Financial Performance

In 2024, Arcutis Biotherapeutics's revenue was $196.54 million, an increase of 229.74% compared to the previous year's $59.61 million. Losses were -$140.04 million, -46.58% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price target is $22.17, which is a decrease of -24.82% from the latest price.

Price Target

$22.17

(-24.82% downside)

Analyst Consensus: Strong Buy